東瑞製葯(控股)有限公司

In the situation where the growing correlated economy among the whole world of today and the entry of WTO of China has given rise to some necessary changes, the whole pharmaceutical industry of China has been meeting with an unprecedented challenge, let alone all those newcomers to the industry like Dawnrays. After the beginning development stage, Dawnrays is now at the stage, where it is considered crucial for it.

With the continuing efforts for Dawnrays as beginner for the past ten years, early stage of foundation of continuing advancing development has been established. And now, in meeting with the expectation of the shareholders and colleagues, Dawnrays will therefore be expected to advance toward further development at a more rapid pace. With this expectation, Dawnrays is prepared to have great regard for direction of further development with a careful strategy in order to ascertain the target goal..

Dawnrays' whole family members are in a position to advance toward the same goals in common without regard to how great the changes are from time to time in the future – namely that a pharmaceutical manufacturer possesses such factors as lively, modernization and globalization, and, that Dawnrays will occupy the top spot in the industry and this will in turn be to form the foundation of Dawnrays' hundreds years of pathway to lead the industry ahead. For this reason, Dawnrays has long been the concentration of people to realize their own values by contribution of their expertise to complement each other. With all possible obstacles in the pathway being realized, Dawnrays-member understood that brave would overcome difficulty. It is a belief that facing difficulty without hesitation is a primary condition for people to reach the peak of career path.

Dawnrays Pharmaceutical R & D Centre, with professional innovative enduring spirit, is carrying on the responsibility of development of new drug for all possible improvements in drug production techniques. It is situate in an independent building equipped with advanced experimental devices and comprehensive pro-test workshop.

The R & D centre has always been committing the management principle of “people come first”. It forms a group of rigorous and strong R & D teammates, consisting of experienced experts with professional qualifications ranging from the master degree to doctoral degree in the industry. Senior researchers possess wide range of knowledge in pharmacology, pharmacy, clinical practice and chemical engineering synthesis as a matter of our standard requirements.

The direction of our R & D centre is market-driven. With continuous efforts in technological innovations and R & D strategies, Dawnrays R & D centre has been producing high quality drugs at reasonable price to the market, focusing on the research and development of cephalosporin and system specific medicines. Our R & D capability has been recognized as the leading position in China, especially our well-known third generation cephalosporin product series. Since the establishment of Dawnrays R & D centre, there were 64 numbers of drugs production permits obtained, of which 15 of them were new.

Dawnrays R & D centre is concerned with R & D exposures such as overseas exchange and cooperation. R & D centre has good relations and close connections with other technology companies, universities, technological institutions and experts in R & D for possible communications, sharing knowledge and cooperation. Our R & D centre also welcomes any strategic partnership or cooperation for medical research, drug development, and technology improvement.

Suzhou Dawnrays Pharmaceuticals Co. Ltd. was one of the early pharmaceutical companies among the industry in China that had satisfied all those requirements of the GMP certificates. The company is equipped with top production facilities that complied with all GMP regulations, adequate manpower and management software to support our production capacity of bulk medicines and preparations.

Complied with all GMP regulations, quality-driven, technology-focused and cost control.

Sales & Distribution Management

Our sales and distribution network has been established since 1998. With the mission of service excellence, our sales and distribution channels can cover 30 provinces and cities of our sales network over China, which has occupied over 95% of the whole market coverage.

Dawnrays understood the complications of the China market. According to the product types, regions, distribution channels and market needs, we established four sales divisions, namely Generic Division, Bulk Drugs Division, Neo-Pharm Division and Business Division to adapt the different market needs accordingly. We have built up an efficient, professional and system to satisfy the needs of our sales and distribution channels.

Dawnrays Pharmaceutical is committed to provide high-end quality of service to our clients. Most of our staffs from the sales division have attained the professional qualifications of medical doctors or pharmacists, with professional training including medical knowledge, product knowledge, market analysis, client-servicing, negotiation and legal agreement knowledge. The sales staffs promote our products through various kinds of academic promotions, or direct marketing to the end-users by providing consumers education and training.